Sistema de Salut de Catalunya
Institut Català de la Salut
[Agarwal N] Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. [Saad F] University of Montréal Hospital Center, Montréal, Québec, Canada. [Azad AA] Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Matsubara N] National Cancer Center Hospital East, Chiba, Japan. [Shore ND] Carolina Urologic Research Center, Myrtle Beach, SC, USA
Vall d'Hebron Barcelona Hospital Campus
2024-03-27T08:57:30Z
2024-03-27T08:57:30Z
2023-10-26
PARP inhibitor; Androgen receptor; Enzalutamide
Inhibidor de PARP; Receptor de andrógenos; Enzalutamida
Inhibidor de PARP; Receptor d'andrògens; Enzalutamida
Poly(ADP-ribose) polymerase inhibitors in combination with androgen-receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations. Here, we describe the design and rationale of the multinational, phase III, TALAPRO-3 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with mCSPC and HRR gene alterations. The primary end point is investigator-assessed radiographic progression-free survival (rPFS) per RECIST 1.1 in soft tissue, or per PCWG3 criteria in bone. The TALAPRO-3 study will demonstrate whether the addition of talazoparib can improve the efficacy of enzalutamide as assessed by rPFS in patients with mCSPC and HRR gene alterations undergoing androgen deprivation therapy. Clinical Trial Registration:NCT04821622 (ClinicalTrials.gov) Registry Name: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC. Date of Registration: 29 March 2021.
This study was sponsored by Pfizer. Astellas Pharma Inc. provided enzalutamide.
Article
Published version
English
Pròstata - Càncer - Tractament; Metàstasi; Antiandrògens - Receptors; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Androgen Antagonists::Androgen Receptor Antagonists; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de andrógenos::antagonistas de receptores de andrógenos; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
Future Medicine
Future Oncology;20(9)
https://doi.org/10.2217/fon-2023-0526
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]
